Hypothesis

Aged dendritic cells exhibit a shift in autophagy receptor selectivity driven by phosphorylation of p62, which redirects the autophagic machinery to degrade TLR adaptor proteins while leaving negative regulators intact.

Mechanistic model

1. Baseline signaling – In older individuals, persistent low‑grade inflammation maintains mTORC1 and ERK1/2 activity in dendritic cells.

2. p62 modification – These kinases phosphorylate p62 on Ser403 and Ser407, reducing its affinity for K48‑linked ubiquitin and increasing binding to K63‑linked chains.

3. Selective cargo – Phospho‑p62 now preferentially captures ubiquitinated MyD88 and TRIF (K63‑linked) for ATG5‑dependent lysosomal degradation, whereas A20 (largely K48‑linked) is poorly recognized and therefore accumulates.

4. Outcome – Loss of MyD88/TRIF dampens TLR‑stimulated NF‑κB and IRF signaling, yet excess A20 fails to curb basal inflammasome activity, leading to high basal TNF‑α/IL‑6 and poor vaccine‑induced cytokine bursts.

Testable predictions

• Prediction 1 – Pharmacological inhibition of mTORC1 (rapamycin) or ERK (U0126) in aged dendritic cells will reduce p62 phosphorylation, restore MyD88/TRIF levels, and rescue TLR‑stimulated cytokine production.

• Prediction 2 – Expression of a phospho‑deficient p62 mutant (S403A/S407A) in aged DCs will mimic the young phenotype: normal adaptor degradation, balanced A20 turnover, and improved influenza vaccine‑specific antibody titers in mice.

• Prediction 3 – Mass‑spectrometry‑based ubiquitin linkage analysis of immunoprecipitated p62 from young versus aged DCs will show a shift from K48‑ to K63‑linked ubiquitin enrichment in the aged condition.

Experimental approach

• Isolate bone‑marrow‑derived dendritic cells (BMDCs) from young (8 wk) and aged (20 mo) C57BL/6 mice.

• Treat cells with rapamycin (100 nM) or U0126 (10 µM) for 2 h, then stimulate with LPS (TLR4) or R848 (TLR7/8).

• Measure MyD88, TRIF, A20 protein levels by western blot; assess phospho‑p62 by Phos‑tag gel.

• Quantify cytokines (TNF‑α, IL‑6, IL-12p40) in supernatants via ELISA.

• In parallel, transfect aged BMDCs with lentiviral vectors encoding WT p62 or S403A/S407A mutant, then repeat TLR stimulation and cytokine read‑out.

• For in vivo validation, adoptively transfer WT or mutant p62‑expressing aged DCs into aged mice prior to immunization with inactivated H3N2 influenza; evaluate serum hemagglutination inhibition titers at day 14.

• Perform ubiquitin linkage profiling using tandem ubiquitin binding entity (TUBE) pull‑down followed by LC‑MS/MS to compare K48/K63 ratios on p62‑associated cargo.

Potential pitfalls and alternatives

• Compensatory upregulation of other autophagy receptors (NBR1, OPTN) may mask p62 effects; double‑knockout experiments can address this.

• Chronic rapamycin treatment may affect DC survival; short‑term ex‑vivo pretreatment minimizes toxicity.

• If phospho‑deficient p62 does not rescue function, investigate alternative phosphorylation sites (Ser349, Ser351) or consider redox‑dependent modifications of p62 cysteine residues driven by mitochondrial ROS.

This hypothesis directly links an age‑dependent post‑translational tweak of the autophagy hierarchy to the divergent basal‑high/stimulated‑low cytokine signature that undermines vaccine efficacy, offering a clear, falsifiable roadmap for therapeutic targeting.